Trevi Therapeutics (TRVI): Raymond James Sees 409% Upside Potential After Phase 2a RIVER Study Update!

Trevi Therapeutics (TRVI) is a biotech company focusing on the development of Haduvio (oral Nalbuphine ER). Haduvio is a drug being developed by Trevi Therapeutics aimed at helping people suffering from severe and persistent cough, particularly in certain conditions such as idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). IPF is being addressed through the CORAL study, while RCC is the focus of the RIVER study. What makes Haduvio special is its dual action on the nervous system in the brain as well as on the nerves in the...